We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.
- Authors
Melosky, B.; Agulnik, J.; Albadine, R.; Banerji, S.; Bebb, D. G.; Bethune, D.; Blais, N.; Butts, C.; Cheema, P.; Cheung, P.; Cohen, V.; Deschenes, J.; Ionescu, D. N.; Juergens, R.; Kamel-Reid, S.; Laurie, S. A.; Liu, G.; Morzycki, W.; Tsao, M. S.; Xu, Z.
- Abstract
Anaplastic lymphoma kinase (ALK) is an oncogenic driver in non-small-cell lung cancer (NSCLC). Chromosomal rearrangements involving the ALK gene occur in up to 4% of nonsquamous NSCLC patients and lead to constitutive activation of the ALK signalling pathway. ALK-positive NSCLC is found in relatively young patients, with a median age of 50 years. Patients frequently have brain metastasis. Targeted inhibition of the ALK pathway prolongs progression-free survival in patients with ALK-positive advanced NSCLC. The results of several recent clinical trials confirm the efficacy and safety benefit of crizotinib and ceritinib in this population. Canadian oncologists support the following consensus statement: All patients with advanced nonsquamous NSCLC (excluding pure neuroendocrine carcinoma) should be tested for the presence of an ALK rearrangement. If an ALK rearrangement is present, treatment with a targeted ALK inhibitor in the first-line setting is recommended. As patients become resistant to first-generation ALK inhibitors, other treatments, including second-generation ALK inhibitors can be considered.
- Subjects
ANAPLASTIC lymphoma kinase; SMALL cell lung cancer; BRAIN metastasis; PROGRESSION-free survival; DRUG efficacy
- Publication
Current Oncology, 2016, Vol 23, Issue 3, p196
- ISSN
1198-0052
- Publication type
Article
- DOI
10.3747/co.23.3120